Skip to main content
. 2016 May 13;6(5):e419. doi: 10.1038/bcj.2016.28

Figure 1.

Figure 1

A consort diagram of genetic analysis of 373 patients. Samples were obtained from patients treated in the TCCSG (n=160), JACLS (n=112), CCLSG (n=83) and KYCCSG (n=18) cohorts. Ninety-two of the 160 in the TCCSG cohort and 17 of the 112 in the JACLS cohort were analyzed by mRNA-seq. The remaining 264 patients were analyzed by mRT-PCR. The kinase-activating fusions were identified in 16 of the 109 by mRNA-seq and in 13 of the 264 by mRT-PCR.